| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802579501012 | 257950101 | SIMVALID F.C.TAB 20MG/TAB BTX10(BLIST 1X10) | 1.94 | 02.03 | 2.80 |
| 05/2018 | 2802579501029 | 257950102 | SIMVALID F.C.TAB 20MG/TAB BTX30(BLIST 3X10) | 5.17 | 5.42 | 7.47 |
| 05/2018 | 2802579502019 | 257950201 | SIMVALID F.C.TAB 40MG/TAB BTX10(BLIST 1X10) | 2.80 | 2.94 | 04.05 |
| 05/2018 | 2802579502026 | 257950202 | SIMVALID F.C.TAB 40MG/TAB BTX30(BLIST 3X10) | 6.99 | 7.33 | 10.10 |
For the treatment of hypercholesterolemia.
The 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.
Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues.
3 hours
Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.